Pharmacielo Financials

PCLO Stock  CAD 0.09  0.01  13.33%   
We recommend to use Pharmacielo fundamental analysis to find out if markets are presently mispricing the firm. Put it differently this technique allows you to confirm available drivers of Pharmacielo as well as the relationship between them. We were able to break down and interpolate thirty-one available financial ratios for Pharmacielo, which can be compared to its competitors. The stock experiences a very speculative upward sentiment. Check odds of Pharmacielo to be traded at C$0.1063 in 90 days. Key indicators impacting Pharmacielo's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio0.150.1553
Sufficiently Down
Slightly volatile
  
Understanding current and past Pharmacielo Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Pharmacielo's financial statements are interrelated, with each one affecting the others. For example, an increase in Pharmacielo's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Pharmacielo's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pharmacielo. Check Pharmacielo's Beneish M Score to see the likelihood of Pharmacielo's management manipulating its earnings.

Pharmacielo Stock Summary

Pharmacielo competes with Cannara Biotech, IShares Canadian, Altagas Cum, European Residential, and RBC Discount. PharmaCielo Ltd., through its subsidiary, PharmaCielo Colombia Holdings S.A.S., cultivates, processes, produces, and supplies medicinal-grade cannabis oil extracts and related products in Colombia and internationally. The company was formerly known as Pan American Cannabis Inc. and changed its name to PharmaCielo Ltd. in September 2014. PHARMACIELO LTD is traded on TSX Venture Exchange in Canada.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeTSX Venture Exchange
ISINCA71716K1012
Business Address82 Richmond Street
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.pharmacielo.com
Phone416 315 8741
CurrencyCAD - Canadian Dollar
You should never invest in Pharmacielo without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Pharmacielo Stock, because this is throwing your money away. Analyzing the key information contained in Pharmacielo's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Pharmacielo Key Financial Ratios

There are many critical financial ratios that Pharmacielo's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Pharmacielo reports annually and quarterly.

Pharmacielo Key Balance Sheet Accounts

201920202021202220232024 (projected)
Total Assets50.2M44.0M36.0M25.1M22.3M26.0M
Net Tangible Assets63.2M43.7M26.1M19.3M22.2M34.0M
Retained Earnings(97.5M)(141.3M)(167.9M)(182.4M)(198.7M)(188.8M)
Accounts Payable2.9M11.7M7.7M6.1M7.0M5.4M
Cash13.7M8.9M5.3M173.0K62.2K59.1K
Net Receivables1.8M924.1K565.2K670.7K229.1K217.7K
Total Liab4.7M17.8M16.6M18.7M24.0M25.2M
Total Current Assets19.7M12.5M9.2M4.0M3.3M3.2M
Common Stock116.8M138.1M156.3M161.7M186.0M93.1M
Net Debt(12.1M)(4.4M)3.1M12.4M18.2M19.1M
Net Invested Capital45.5M29.4M26.5M18.7M16.6M21.5M
Net Working Capital16.4M462.0K1.1M(2.9M)(18.1M)(17.2M)
Inventory3.6M1.3M2.3M2.1M2.3M2.1M
Other Current Assets426.6K732.1K721.3K889.2K800.3K760.3K
Capital Stock116.8M138.1M156.3M161.7M166.0M135.5M

Pharmacielo Key Income Statement Accounts

201920202021202220232024 (projected)
Interest Expense173.8K272.7K561.3K1.5M2.7M2.8M
Gross Profit(1.7M)(6.8M)(4.3M)827.1K(1.4M)(1.4M)
Operating Income(34.0M)(43.1M)(25.5M)(11.5M)(10.0M)(10.5M)
Ebit(34.0M)(43.1M)(25.5M)(11.5M)(10.3M)(10.8M)
Cost Of Revenue2.4M9.5M6.3M4.5M2.9M3.5M
Income Before Tax(34.7M)(43.8M)(26.6M)(14.5M)(16.3M)(17.1M)
Net Income(34.6M)(44.3M)(26.9M)(16.0M)(16.3M)(17.1M)
Income Tax Expense(44.9K)504.4K288.0K1.5M1.7M1.8M
Total Revenue786.9K2.7M1.9M5.3M1.5M2.2M
Ebitda(32.7M)(41.6M)(24.2M)(9.9M)(8.9M)(9.3M)

Pharmacielo Key Cash Accounts

201920202021202220232024 (projected)
Change To Inventory(2.7M)(4.7M)(3.4M)(1.0M)746.1K783.4K
Change In Cash(32.0M)(4.8M)(3.5M)(5.2M)(129.9K)(136.4K)
Depreciation1.3M1.6M1.3M1.6M1.4M1.1M
Capital Expenditures10.7M5.4M1.1M521.9K15.3K14.5K
Net Income(34.7M)(43.8M)(26.6M)(14.5M)(16.3M)(17.1M)
Change To Netincome19.4M10.9M16.8M12.9M14.8M12.8M
End Period Cash Flow13.7M8.9M5.3M173.0K62.2K59.1K
Free Cash Flow(35.9M)(28.0M)(21.2M)(10.2M)(5.2M)(5.4M)

Pharmacielo Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Pharmacielo's current stock value. Our valuation model uses many indicators to compare Pharmacielo value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmacielo competition to find correlations between indicators driving Pharmacielo's intrinsic value. More Info.
Pharmacielo is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, Pharmacielo's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmacielo's earnings, one of the primary drivers of an investment's value.

Pharmacielo Systematic Risk

Pharmacielo's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Pharmacielo volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Pharmacielo correlated with the market. If Beta is less than 0 Pharmacielo generally moves in the opposite direction as compared to the market. If Pharmacielo Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Pharmacielo is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Pharmacielo is generally in the same direction as the market. If Beta > 1 Pharmacielo moves generally in the same direction as, but more than the movement of the benchmark.

Pharmacielo Total Assets Over Time

Today, most investors in Pharmacielo Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pharmacielo's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Pharmacielo growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.2

At this time, Pharmacielo's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Pharmacielo November 28, 2024 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Pharmacielo help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Pharmacielo. We use our internally-developed statistical techniques to arrive at the intrinsic value of Pharmacielo based on widely used predictive technical indicators. In general, we focus on analyzing Pharmacielo Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Pharmacielo's daily price indicators and compare them against related drivers.

Additional Tools for Pharmacielo Stock Analysis

When running Pharmacielo's price analysis, check to measure Pharmacielo's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmacielo is operating at the current time. Most of Pharmacielo's value examination focuses on studying past and present price action to predict the probability of Pharmacielo's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmacielo's price. Additionally, you may evaluate how the addition of Pharmacielo to your portfolios can decrease your overall portfolio volatility.